Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 6051 - 6075 of 6770 in total
Investigational
Tasisulam has been used in trials studying the treatment and basic science of Melanoma, Lymphoma, Solid Tumors, Breast Cancer, and Ovarian Cancer, among others.
Investigational
Investigational
Tiapride is a selective D2 and D3 dopamine receptor blocker in the brain.
Investigational
Dovramilast is under investigation in clinical trial NCT01300208 (To Evaluate the Preliminary Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of CC-11050 in Subjects With Discoid Lupus Erythematosus and Subacute Cutaneous Lupus Erythematosus).
Investigational
PIK3CA is under investigation in clinical trial NCT02957266 (Cervical Cancer Radiotherapy by Use of VMAT, Individualized Polyradiosensitization and Interstitial Brachytherapy).
Investigational
Investigational
Rusfertide is a hepcidin mimetic currently being developed by Protagonist Therapeutics for the treatment of polycythemia vera and beta-thalassemia.
Investigational
Izuralimab is under investigation in clinical trial NCT05879185 (A Study of Xmab23104 in People With Sarcoma).
Investigational
RAD140 is an investigational selective androgen receptor modulator (SARM) for the treatment of conditions such as muscle wasting and breast cancer.
Experimental
Investigational
Investigational
Aprobarbital is a barbiturate derivative synthesized in the 1920s by Ernst Preiswerk. It was determined that the substance was capable of demonstrating sedative, hypnotic, and anticonvulsant effects. A primary treatment indicated for the use of aprobarbital was subsequently insomnia. Aprobarbital was never as widely used as more common barbiturate derivatives...
Experimental
Illicit
Vet approved
Experimental
Experimental
Andarine is a non-steroidal selective androgen receptor modulator.
Experimental
Investigational
Investigational
RGX-111 is an adeno-associated virus vector AAV9 designed to deliver the α-L-iduronidase (IDUA) gene. Developed by REGENXBIO Inc., it was investigated for the treatment of mucopolysaccharidosis Type I (MPS I).
Investigational
APL-030 is a orally-active small molecule inhibitor of GCN2.
Investigational
Displaying drugs 6051 - 6075 of 6770 in total